Drugs / Paprizumab
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT05444673 | Jun 2022 → Jun 2023 | bone squamous cell carcinoma | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Paprizumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05444673 ↗ |
| Action | Inhibit | “blocks the interaction between PD1 and the dura mater” NCT05444673 ↗ |
| Modality | Monoclonal antibody | “is a monoclonal antibody to PD1” NCT05444673 ↗ |
| Route | Intravenous | “paprizumab (200mg iv, 21-day cycle)” NCT05444673 ↗ |